Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2777-2784

  Ye, Yan Wei ^a   Hu, Shuang ^a   Shi, Ying Qiang ^b,c   Zhang, Xie Fu ^a   Zhou, Ye ^b,c   Zhao, Chun Lin ^a   Wang, Guo Jun ^a   Wen, Jian Guo ^a   Zong, Hong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; FGFR4; Gastric cancer; MKN45; PD173074

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; CASPASE 3; CHOLECYSTOKININ OCTAPEPTIDE; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL FUNCTION; CELL STRAIN MKN45; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84892398653     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2796     Document Type: Article

References (19)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Katoh M: Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 10: 1375-1379, 2010.
3. Wang J, Stockton DW and Ittmann M: The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10: 6169-6178, 2004.
4. Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149, 2005.
5. Ye Y, Shi Y, Zhou Y, et al: The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol 12: 3354-3361, 2010.
6. Ye YW, Zhou Y, Yuan L, et al: Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. Cancer 117: 5304-5313, 2011.
7. Ho HK, Pok S, Streit S, et al: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-127, 2009.
8. Trudel S, Ely S, Farooqi Y, et al: Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103: 3521-3528, 2004.
9. Pardo OE, Latigo J, Jeffery RE, et al: The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69: 8645-8651, 2009.
10. Koziczak M and Hynes NE: Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 279: 50004-50011, 2004.
11. Ezzat S, Huang P, Dackiw A, et al: Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11: 1336-1341, 2005.
12. St. Bernard R, Zheng L, Liu W, et al: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146: 1145-1153, 2005.
13. Xie MH, Holcomb I, Deuel B, et al: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735, 1999.
14. Harmer NJ, Pellegrini L, Chirgadze D, et al: The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43: 629-640, 2004.
15. Wu X, Ge H, Lemon B, et al: Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 106: 14379-14384, 2009.
16. Wu X, Ge H, Lemon B, et al: FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 285: 5165-5170, 2010.
17. Inagaki T, Choi M, Moschetta A, et al: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.
18. Roidl A, Berger HJ, Kumar S, et al: Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 15: 2058-2066, 2009.
19. Drafahl KA, McAndrew CW, Meyer AN, et al: The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling. PLoS One 5: e14412, 2010.